Cochrane · systematic review · CD012912
Nifedipine for primary dysmenorrhoea
Earl, RA, Grivell, RM · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 5 · 83.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Nifedipine compared to placebo for primary dysmenorrhoea
Population: primary dysmenorrhoea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain relief (any) Nifedipine vs placebo | OR 9.04 [2.61, 31.31] | 2 studies · 66 participants | Very low Downgraded: risk of bias, imprecision |
Good or excellent pain relief Nifedipine vs placebo | OR 43.78 [5.34, 359.01] | 2 studies · 66 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Nifedipine vs placebo | no estimate extracted | NR | No studies |
Total adverse effects Nifedipine vs placebo | OR 0.94 [0.08, 10.9] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Bothersome adverse effects Nifedipine vs placebo | OR 0.54 [0.07, 4.2] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Requirement for additional medication Nifedipine vs placebo | OR 0.07 [0.02, 0.32] | 1 study · 42 participants | Very low Downgraded: risk of bias |